Belite Bio
BLTE
7 hedge funds and large institutions have $25.9M invested in Belite Bio in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.
568% more capital invested
Capital invested by funds: $3.87M → $25.9M (+$22M)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
2.98% more ownership
Funds ownership: 0.46% → 3.45% (+3%)
13% less funds holding
Funds holding: 8 → 7 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWS
Atria Wealth Solutions
New York
|
+$22.3M |
| 2 |
AA
ALPS Advisors
Denver,
Colorado
|
+$474K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$124K |
| 4 |
State Street
Boston,
Massachusetts
|
+$34.2K |
| 5 |
BlackRock
New York
|
+$25.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$481K |
| 2 |
JP Morgan Chase
New York
|
-$250K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$245K |
| 4 |
Barclays
London,
United Kingdom
|
-$223K |
| 5 |
PWMG
Prestige Wealth Management Group
Flemington,
New Jersey
|
-$7K |
BLTE Hedge Fund Activity: Q4 2022 in Review
7 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Belite Bio (BLTE) for Q4 2022, worth a combined $25.9M — up 568% from $3.87M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BLTE and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was Atria Wealth Solutions, adding an estimated $22.3M. The largest seller was Morgan Stanley, cutting an estimated $481K.
- 7 institutional investors held Belite Bio (BLTE) as of Q4 2022, down from 8 in Q3 2022.
- Funds reported $25.9M of Belite Bio stock for Q4 2022, up 568% quarter-over-quarter.
- 3 funds opened new Belite Bio positions in Q4 2022 and 4 closed out, a net change of -1 holder.
- The largest Belite Bio buyer in Q4 2022 was Atria Wealth Solutions, an estimated $22.3M added.
- The largest Belite Bio seller in Q4 2022 was Morgan Stanley, an estimated $481K sold.
Based on aggregated 13F filings for Q4 2022.